Clinical Trial Update: A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion [Phase 2]

View source ↗

Summary

Phase 2 trial update for Alg-1001 in symptomatic focal vitreomacular adhesion has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Symptomatic Focal Vitreomacular Adhesion

Drugs mentioned

• ALG-1001

Snippet

Sponsor: Allegro Ophthalmics, LLC | Conditions: Symptomatic Focal Vitreomacular Adhesion | Phase 2 | Status: COMPLETED | Results posted: 2018-07-18